Iota-Carrageenan is a potent inhibitor of rhinovirus infection

Virology Journal

Volumn 5, Issue , 2008, Pages

  Grassauer, Andreas ^a,b   Weinmuellner, Regina ^a   Meier, Christiane ^a,b   Pretsch, Alexander ^a,b   Prieschl Grassauer, Eva ^a,b   Unger, Hermann ^b  

^a Marinomed Biotechnologie GmbH   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS; IN VITRO STUDY; NOSE MUCOSA; RHINOVIRUS; VIRUS INFECTION; CELL CULTURE; CELL SURVIVAL; CLASSIFICATION; COMMON COLD; HELA CELL; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

HUMAN RHINOVIRUS SP.; RHINOVIRUS;

ANTIVIRAL AGENTS; CARRAGEENAN; CELL SURVIVAL; CELLS, CULTURED; COMMON COLD; HELA CELLS; HUMANS; NASAL MUCOSA; RHINOVIRUS; VIRUS REPLICATION;

EID: 53649101500     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-107     Document Type: Article

References (34)

1. Host and virus determinants of picornavirus pathogenesis and tropism. JL Whitton CT Cornell R Feuer, Nat Rev Microbiol 2005 3 765 776 10.1038/nrmicro1284 16205710
2. Diagnosis and treatment of rhinovirus respiratory infections. A Anzueto MS Niederman, Chest 2003 123 1664 1672 10.1378/chest.123.5.1664 12740288
3. New developments in the epidemiology and clinical spectrum of rhinovirus infections. JW Brownlee RB Turner, Curr Opin Pediatr 2008 20 67 71 10.1097/MOP.0b013e3282f41cb6 18197042
4. Rhinoviruses: important respiratory pathogens. A Pitkaranta FG Hayden, Ann Med 1998 30 529 537 10.3109/07853899809002600 9920354
5. Selective inhibitors of picornavirus replication. AM De Palma I Vliegen CE De J Neyts, Med Res Rev 2008 18381747
6. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. FG Hayden RB Turner JM Gwaltney K Chi-Burris M Gersten P Hsyu AK Patick GJ Smith III LS Zalman, Antimicrob Agents Chemother 2003 47 3907 3916 14638501 10.1128/AAC.47.12.3907-3916.2003
7. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. FG Hayden DT Herrington TL Coats K Kim EC Cooper SA Villano S Liu S Hudson DC Pevear M Collett M McKinlay, Clin Infect Dis 2003 36 1523 1532 10.1086/375069 12802751
8. Combined antiviral-antimediator treatment for the common cold. JM Gwaltney Jr B Winther JT Patrie JO Hendley, J Infect Dis 2002 186 147 154 10.1086/341455 12134249
9. Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. FG Hayden JM Gwaltney Jr, J Infect Dis 1984 150 174 180 6381610
10. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. FG Hayden JK Albrecht DL Kaiser JM Gwaltney Jr, N Engl J Med 1986 314 71 75 3001519
11. Polysaccharides as antiviral agents: antiviral activity of carrageenan. ME Gonzalez B Alarcon L Carrasco, Antimicrob Agents Chemother 1987 31 1388 1393 2823697
12. Carrageenan is a potent inhibitor of papillomavirus infection. CB Buck CD Thompson JN Roberts M Muller DR Lowy JT Schiller, PLoS Pathog 2006 2 e69 16839203 10.1371/journal.ppat.0020069
13. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice. MJ Carlucci LA Scolaro MD Noseda AS Cerezo EB Damonte, Antiviral Res 2004 64 137 141 15498610
14. Antiviral activity of a carrageenan from Gigartina skottsbergii against intraperitoneal murine herpes simplex virus infection. CA Pujol LA Scolaro M Ciancia MC Matulewicz AS Cerezo EB Damonte, Planta Med 2006 72 121 125 10.1055/s-2005-373168 16491446
15. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. M Baba R Snoeck R Pauwels CE De, Antimicrob Agents Chemother 1988 32 1742 1745 2472775
16. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. LB Talarico CA Pujol RG Zibetti PC Faria MD Noseda ME Duarte EB Damonte, Antiviral Res 2005 66 103 110 10.1016/j.antiviral.2005.02.001 15911027
17. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. RM Ledford NR Patel TM Demenczuk A Watanyar T Herbertz MS Collett DC Pevear, J Virol 2004 78 3663 3674 15016887 10.1128/JVI.78.7.3663-3674.2004
18. Antiherpetic and anticoagulant properties of carrageenans from the red seaweed Gigartina skottsbergii and their cyclized derivatives: correlation between structure and biological activity. MJ Carlucci CA Pujol M Ciancia MD Noseda MC Matulewicz EB Damonte AS Cerezo, Int J Biol Macromol 1997 20 97 105 10.1016/S0141-8130(96)01145-2 9184941
19. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice. MJ Carlucci LA Scolaro MD Noseda AS Cerezo EB Damonte, Antiviral Res 2004 64 137 141 15498610
20. Carrageenan/MIV-150 (PC-815), a combination microbicide. JA Fernandez-Romero M Thorn SG Turville K Titchen K Sudol J Li T Miller M Robbiani RA Maguire RW Buckheit Jr TL Hartman DM Phillips, Sex Transm Dis 2007 34 9 14 10.1097/01.olq.0000223287.46097.4b 16924181
21. Antiviral activity of carrageenan on hepatitis A virus replication in cell culture. S Girond JM Crance H Van Cuyck-Gandre J Renaudet R Deloince, Res Virol 1991 142 261 270 10.1016/0923-2516(91)90011-Q 1665574
22. Inhibition by iota-carrageenan of the spread of murine cytomegalovirus from the peritoneal cavity to the blood plasma. R Hamasuna Y Eizuru Y Minamishima, J Gen Virol 1994 75 Pt 1 111 116 10.1099/0022-1317-75-1-111 8113719
23. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. AR Neurath N Strick YY Li, BMC Infect Dis 2002 2 27 12445331 10.1186/1471-2334-2-27
24. Interference in dengue virus adsorption and uncoating by carrageenans. LB Talarico EB Damonte, Virology 2007 363 473 485 10.1016/j.virol.2007.01.043 17337028
25. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. M Witvrouw CE De, Gen Pharmacol 1997 29 497 511 10.1016/S0306-3623(96) 00563-0 9352294
26. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. C Cabrera M Witvrouw A Gutierrez B Clotet ME Kuipers PJ Swart DK Meijer J Desmyter CE De JA Este, AIDS Res Hum Retroviruses 1999 15 1535 1543 10.1089/088922299309829 10580404
27. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. JA Este D Schols VK De LK Van AM Vandamme J Desmyter CE De, Mol Pharmacol 1997 52 98 104 9224818
28. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. E Arruda TR Boyle B Winther DC Pevear JM Gwaltney Jr FG Hayden, J Infect Dis 1995 171 1329 1333 7751712
29. Detection of rhinovirus infection of the nasal mucosa by oligonucleotide in situ hybridization. PG Bardin SL Johnston G Sanderson BS Robinson MA Pickett DJ Fraenkel ST Holgate, Am J Respir Cell Mol Biol 1994 10 207 213 8110476
30. Human rhinovirus infection induces airway epithelial cell production of human beta-defensin 2 both in vitro and in vivo. D Proud SP Sanders S Wiehler, J Immunol 2004 172 4637 4645 15034083
31. Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. JC Spurrell S Wiehler RS Zaheer SP Sanders D Proud, Am J Physiol Lung Cell Mol Physiol 2005 289 L85 L95 10.1152/ajplung.00397.2004 15764644
32. Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. B Jakiela R Brockman-Schneider S Amineva WM Lee JE Gern, Am J Respir Cell Mol Biol 2008 38 517 523 10.1165/rcmb.2007-0050OC 18063839
33. The cold case: are rhinoviruses perfectly adapted pathogens? S Dreschers CA Dumitru C Adams E Gulbins, Cell Mol Life Sci 2007 64 181 191 10.1007/s00018-006-6266-5 17131060
34. A simple method of estimating fifty percent endpoints. LJ Reed H Muench, Am J Hyg 1938 493 497